Výsledky vyhledávání

Akademický článek

Non-covalent SARS-CoV-2 M ^pro inhibitors developed from in silico screen hits.

Autor: Rossetti GG; Department of Molecular Biology, University of Geneva, 1205, Geneva, Switzerland.; FoRx Therapeutics AG, 4056, Basel, Switzerland., Ossorio MA; Department of Molecular Biology, University of Geneva, 1205, Geneva, Switzerland., Rempel S; FoRx Therapeutics AG, 4056, Basel, Switzerland., Kratzel A; Institute of Virology and Immunology, University of Bern, 3012, Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland.; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland., Dionellis VS; Department of Molecular Biology, University of Geneva, 1205, Geneva, Switzerland., Barriot S; Department of Molecular Biology, University of Geneva, 1205, Geneva, Switzerland., Tropia L; Department of Molecular Biology, University of Geneva, 1205, Geneva, Switzerland., Gorgulla C; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, MA, 02115, USA.; Department of Physics, Faculty of Arts and Sciences, Harvard University, Cambridge, MA, 02138, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Arthanari H; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, MA, 02115, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Thiel V; Institute of Virology and Immunology, University of Bern, 3012, Bern, Switzerland.; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, 3012, Bern, Switzerland., Mohr P; NANDASI Pharma Advisors, 4123, Allschwil, Switzerland., Gamboni R; NANDASI Pharma Advisors, 4123, Allschwil, Switzerland., Halazonetis TD; Department of Molecular Biology, University of Geneva, 1205, Geneva, Switzerland. thanos.halazonetis@unige.ch.; FoRx Therapeutics AG, 4056, Basel, Switzerland. thanos.halazonetis@unige.ch.

Publikováno v: Scientific reports [Sci Rep] 2022 Feb 15; Vol. 12 (1), pp. 2505. Date of Electronic Publication: 2022 Feb 15.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Evaluation of bovine milk extracellular vesicles for the delivery of locked nucleic acid antisense oligonucleotides.

Autor: Grossen P; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Portmann M; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Koller E; Roche Pharma Research and Early Development, DMPK, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Duschmalé M; Roche Pharma Research and Early Development, iSafe, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Minz T; Roche Pharma Research and Early Development, iSafe, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Sewing S; Roche Pharma Research and Early Development, iSafe, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Pandya NJ; Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland; Roche Pharma Research and Early Development, Neurology and Rare Diseases Disease Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., van Geijtenbeek SK; Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Ducret A; Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Kusznir EA; Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Huber S; Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Berrera M; Roche Pharma Research and Early Development, Biomics and Pathology, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Lauer ME; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Ringler P; Center for Cellular Imaging and NanoAnalytics (C-CINA), University of Basel, Basel, Switzerland., Nordbo B; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, F. Hoffmann-La Roche Ltd, Fremtidsvej3, 2970 Hoersholm, Denmark., Jensen ML; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, F. Hoffmann-La Roche Ltd, Fremtidsvej3, 2970 Hoersholm, Denmark., Sladojevich F; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Jagasia R; Roche Pharma Research and Early Development, Neurology and Rare Diseases Disease Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Alex R; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Gamboni R; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland., Keller M; Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland. Electronic address: michael.keller.mk5@roche.com.

Publikováno v: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2021 Jan; Vol. 158, pp. 198-210. Date of Electronic Publication: 2020 Nov 26.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání